Adma Biologics Inc’s filing revealed that its President and CEO Grossman Adam S unloaded Company’s shares for reported $0.41 million on May 15 ’25. In the deal valued at $19.45 per share,21,000 shares were sold. As a result of this transaction, Grossman Adam S now holds 2,049,850 shares worth roughly $41.39 million.
Then, Grossman Adam S sold 21,000 shares, generating $450,660 in total proceeds. Upon selling the shares at $21.46, the President and CEO now owns 2,055,850 shares.
Before that, Grossman Adam S sold 21,000 shares. Adma Biologics Inc shares valued at $397,320 were divested by the President and CEO at a price of $18.92 per share. As a result of the transaction, Grossman Adam S now holds 2,061,850 shares, worth roughly $41.63 million.
A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. Raymond James also remained covering ADMA and has increased its forecast on November 11, 2021 with a “Strong buy” recommendation from previously “an Outperform” rating. Cantor Fitzgerald started covering the stock on November 09, 2021. It rated ADMA as “an Overweight”.
Price Performance Review of ADMA
On Monday, Adma Biologics Inc [NASDAQ:ADMA] saw its stock jump 2.54% to $20.19. Over the last five days, the stock has lost -1.27%. Adma Biologics Inc shares have risen nearly 17.73% since the year began. Nevertheless, the stocks have risen 121.87% over the past one year.
How much short interest is there in Adma Biologics Inc?
A steep rise in short interest was recorded in Adma Biologics Inc stocks on 2025-04-30, dropping by -0.62 million shares to a total of 12.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 12.96 million shares. There was a decline of -4.98%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 04, 2019 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
